

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 March 2006 (30.03.2006)

PCT

(10) International Publication Number
WO 2006/032453 A1

(51) International Patent Classification:
C07D 413/12 (2006.01) **A61P 35/00** (2006.01)
A61K 31/422 (2006.01)

(21) International Application Number:
PCT/EP2005/010127

(22) International Filing Date:
20 September 2005 (20.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04 022 371.1 21 September 2004 (21.09.2004) EP

(71) Applicant (for all designated States except US): **F.HOFF-MANN-LA ROCHE AG** [CH/CH]; Grenzacherstr. 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FRIEBE, Walter-Gunar** [DE/DE]; Sophienstrasse 8, 68165 Mannheim (DE). **REIFF, Ulrike** [DE/DE]; Weidenweg 6, 82377 Penzberg (DE). **VON HIRSCHHEYDT, Thomas** [DE/DE]; Im Dittenried 10a, 82377 Penzberg (DE). **VOSS, Edgar** [DE/DE]; Siedlungsstrasse 7, 83673 Bichl (DE).

(74) Agent: **SCHREINER, Siegfried**; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 1,2,3 -TRIAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS



(I)

(57) Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

WO 2006/032453 A1

1,2,3-TRIAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS

The present invention relates to novel triazole derivatives, to a process for their manufacture, pharmaceutical compositions containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents.

- 5 Protein tyrosine kinases (PTKs) catalyse the phosphorylation of tyrosyl residues in various proteins involved in the regulation of cell growth and differentiation (Wilks et al., Progress in Growth Factor Research 97 (1990) 2; Chan, A.C., and Shaw, A.S., Curr. Opin. Immunol. 8 (1996) 394-401). Such PTKs can be divided into receptor tyrosine kinases (e.g. EGFR/HER-1, c-erbB2/HER-2, c-met, PDGFr, FGFr) and non-receptor tyrosine kinases (e.g. src, lck). It is known that many oncogenes encode proteins which are aberrant tyrosine kinases capable of causing cell transformation (Yarden, Y., and Ullrich, A., Annu. Rev. Biochem. 57 (1988) 443-478; Larsen et al., Ann. Reports in Med. Chem., 1989, Chpt. 13). Also over-expression of a normal proto-oncogenic tyrosine kinase may result in proliferative disorders.
- 10
- 15 It is known that receptor tyrosine kinases of the HER-family like HER-2 and EGFR (HER-1) are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer (colon, rectal or stomach cancer), leukaemia and ovarian, bronchial and pancreatic cancer. High levels of these receptors correlate with poor prognosis and response to treatment (Wright, C., et al., Br. J. Cancer 65 (1992) 118-121).
- 20

Accordingly, it has been recognized that inhibitors of receptor tyrosine kinases are useful as selective inhibitors of the growth of mammalian cancer cells. Therefore several small molecule compounds as well as monoclonal antibodies are in clinical trials for the treatment of various types of cancer (Baselga, J., and Hammond, L.A., Oncology 63 (Suppl. 1) (2002) 6-16; Ranson, M., and Sliwkowski, M.X., Oncology 63 (suppl. 1) (2002) 17-24).


25

Some substituted oxazoles are known in the art. WO 98/03505, EP 1 270 571, WO 01/77107, WO 03/031442 and WO 03/059907 disclose related heterocyclic compounds as tyrosine kinase inhibitors.

- 2 -

However there remains a need for new compounds with improved therapeutic properties, such as enhanced activity, decreased toxicity, better solubility and improved pharmacokinetic profile, to name only a few.

The present invention relates to compounds of the general formula I,



formula I,

wherein

R¹ is -O-alkyl or
-S-alkyl; all alkyl groups being optionally substituted one or several
times by halogen;

R² is hydrogen or halogen;

R³ is hydrogen, alkyl or halogen;

W is -C(O)-, -CH(OH)- or -C(alkyl)(OH)-;

and pharmaceutically acceptable salts thereof.

The compounds of the present invention show activity as inhibitors of the HER-signalling pathway and therefore possess anti-proliferative activity. Objects of the present invention are the compounds of formula I and their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture as well as the use of the above-mentioned compounds in the control or prevention of illnesses, especially of illnesses and disorders as mentioned above like common human cancers (e.g. breast cancer, gastrointestinal cancer

- 3 -

(colon, rectal or stomach cancer), leukaemia and ovarian, bronchial and pancreatic cancer) or in the manufacture of corresponding medicaments.

As used herein, the term "alkyl" means a saturated, straight-chain or branched-chain hydrocarbon containing from 1 to 4, preferably 1 or 2, carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, t-butyl.

If said alkyl group is substituted one or several times by halogen, it is substituted preferably by fluorine. Examples are difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl and the like.

The term "halogen" as used herein means fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine or bromine and more preferred fluorine and chlorine.

As used herein, when referring to the receptor tyrosine kinases of the HER-family like HER-2 and EGFR (HER-1), the acronym "HER" refers to human epidermal receptor and the acronym "EGFR" refers to epidermal growth factor receptor.

Preferably R^1 of formula I represents trifluoromethoxy or trifluoromethylsulfanyl, more preferred R^1 of formula I represents trifluoromethoxy.

Preferably the position of R^3 of formula I on the central phenyl ring is meta to the oxazolymethoxy substituent.

An embodiment of the invention are the compounds of formula I, wherein

R^2 is hydrogen; and

R^3 is hydrogen or alkyl.

Still another embodiment of the invention are the compounds of formula I, wherein

R^2 is hydrogen; and

R^3 is hydrogen.

Another embodiment of the invention are the compounds of formula I, wherein

W is -C(O)-.

5 An embodiment of the invention are the compounds of formula I, wherein

R² is hydrogen;

R³ is hydrogen or alkyl; and

10 W is -C(O)-.

Still another embodiment of the invention are the compounds of formula I, wherein

15 R² is hydrogen;

R³ is hydrogen; and

W is -C(O)-.

20 Still another embodiment of the invention are the compounds of formula I, wherein

R¹ is -O-CF₃,
-O-CHF₂, or
-S-CF₃; and

25 W is -C(O)-.

Still another embodiment of the invention are the compounds of formula I, wherein

30 R¹ is -O-CF₃,
-O-CHF₂, or

- 5 -

-S-CF₃; and

R² is hydrogen;

5 R³ is hydrogen or alkyl; and

W is -C(O)-.

10 Still another embodiment of the invention are the compounds of formula I, wherein

R¹ is -O-CF₃,
-O-CHF₂, or
-S-CF₃;

15 R² is hydrogen;

R³ is hydrogen; and

W is -C(O)-.

20

Such compounds are for example:

4-[1,2,3]Triazol-1-yl-1-(4-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-ol; and

25 4-[1,2,3]Triazol-1-yl-1-(4-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one

Another embodiment of the invention are the compounds of formula I, wherein

W is -CH(OH)-.

Another embodiment of the invention are the compounds of formula I, wherein

30 R² is hydrogen;

- 6 -

R^3 is hydrogen or alkyl; and

W is -CH(OH)-.

5

Another embodiment of the invention are the compounds of formula I, wherein

R^2 is hydrogen;

R^3 is hydrogen; and

10

W is -CH(OH)-.

Still another embodiment of the invention are the compounds of formula I, wherein

15

R^1 is -O-CF₃,
-O-CHF₂, or
-S-CF₃; and

W is -CH(OH)-.

20

Still another embodiment of the invention are the compounds of formula I, wherein

R^1 is -O-CF₃,
-O-CHF₂, or
-S-CF₃;

25

R^2 is hydrogen;

R^3 is hydrogen or alkyl; and

30

W is -CH(OH)-.

- 7 -

Still another embodiment of the invention are the compounds of formula I, wherein

5 R¹ is -O-CF₃,
 -O-CHF₂, or
 -S-CF₃;

 R² is hydrogen;

10 R³ is hydrogen; and

 W is -CH(OH)-.

Such a compound is for example:

15 4-[1,2,3]Triazol-1-yl-1-(4-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-ol

Another embodiment of the invention are the compounds of formula I, wherein

 W is -C(alkyl)(OH)-.

Another embodiment of the invention are the compounds of formula I, wherein

20 R² is hydrogen;

 R³ is hydrogen or alkyl; and

25 W is -C(alkyl)(OH)-.

Another embodiment of the invention are the compounds of formula I, wherein

 R² is hydrogen;

 R³ is hydrogen; and

30

- 8 -

W is -C(alkyl)(OH)-.

Still another embodiment of the invention are the compounds of formula I, wherein

5 R¹ is -O-CF₃,
 -O-CHF₂, or
 -S-CF₃, and

W is -C(alkyl)(OH)-.

10

Still another embodiment of the invention are the compounds of formula I, wherein

 R¹ is -O-CF₃,
 -O-CHF₂, or
15 -S-CF₃,

R² is hydrogen;

R³ is hydrogen or alkyl; and

20

W is -C(alkyl)(OH)-.

Still another embodiment of the invention are the compounds of formula I, wherein

25 R¹ is -O-CF₃,
 -O-CHF₂, or
 -S-CF₃, and

R² is hydrogen;

30

R³ is hydrogen; and

W is -C(alkyl)(OH)-.

- 9 -

Still another embodiment of the invention are the compounds of formula I, wherein

5 R^1 is -O-alkyl or
 -S-alkyl; all alkyl groups being substituted one to five, preferably one to
 three times by halogen, preferably by fluorine;

R^2 is hydrogen;

10 R^3 is hydrogen; and

 W is -C(O)- or -CH(OH)-.

15 Still another embodiment of the invention are the compounds of formula I,
 wherein

R^1 is -O-CF₃ or
 -S-CF₃;

20 R^2 is hydrogen;


R^3 is hydrogen; and

 W is -C(O)- or -CH(OH)-.

25 Still another embodiment of the invention is a process for the manufacture of the
 compounds of formula I, wherein

- 10 -


(a) the compound of formula V



formula V,


5 wherein R³ has the significance as given in formula I above and W is -C(O)-,

is reacted with a compound of formula VI




formula VI,

10 wherein R¹ and R² have the significance given in formula I above, to give the respective compound of formula Ia;



formula Ia

- (b) if desired, the compound of formula Ia is reduced to give the respective compound of formula Ib and




formula Ib

- (c) said compound of formula Ia or Ib is isolated from the reaction mixture, and
- (d) if desired, converted into a pharmaceutically acceptable salt.

The derivatives of the general formula I or a pharmaceutically acceptable salt thereof, may be prepared by any process known to be applicable for the preparation of chemically-related compounds by the one skilled in the art. Such processes, when used to prepare the triazole derivatives of formula I, or a pharmaceutically-acceptable salt thereof, are provided as a further feature of the invention and are illustrated by the following representative examples of scheme 1, in which, unless otherwise stated R¹, R² and R³ have the significance given herein before. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.

- 12 -



Scheme 1

Step 1 of scheme 1 represents a standard Friedel-Crafts acylation of the anisoles of formula II with 4-chloro-butyl chloride. The reaction is typically carried out with Lewis acid catalysts like AlCl_3 , AlBr_3 or the like in inert solvents like toluene, tetrahydrofuran (THF) or the like.

- 13 -

Step 2 is a N-alkylation reaction of triazole with the chlorides of formula III. Typically such alkylation is carried out in solvents like DMF, methanol, ethanol and isopropanol. Typical bases for this reaction are alkaline carbonates, sodium methylate, sodium hydride or lithium diisopropyl amide. The reaction
5 temperatures may vary from 20°C to 150°C. Other preferred alkylation procedures make use of alkaline carbonates as bases in solvents like ketones, for example cesium carbonate in 2-butanone at reflux temperature, or sodium hydride in DMF at room temperature.

In Step 3 of scheme 1 the anisole ethers of formula IV are cleaved to release the
10 corresponding phenolic derivatives of formula V. Typically this reaction is carried out with HBr in water or acetic acid under heating. Alternatively HI or other Lewis acids like BF₃, BCl₃, Me₂BBr, Me₃SiI and the like can be used for the ether cleavage.

The derivatives of formula I wherein W is -C(O)- are named Ia and can be obtained by reactions well known to someone skilled in the art, e.g. by alkylation of
15 compounds of formula V with compounds of formula VI according to Step 4 scheme 1. The alkylation can be carried out in the presence of potassium iodide or sodium iodide in solvents like DMF, methanol, ethanol, isopropanol and 2-butanone. Typical bases for this reaction are sodium methylate, sodium hydride, lithium diisopropyl amide or cesium carbonate. The reaction temperatures may
20 vary from 50°C to 150°C.

The derivatives of formula I wherein W is -CH(OH)- are named Ib and can be obtained by reduction of the corresponding ketones of formula Ia. Typically sodium borohydride, diisobutylaluminium hydride (DIBAL) or other reducing reagents are used.

The compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids. Sample acid-addition salts include those derived from
25 inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from
30 organic acids such as p-toluenesulfonic acid, naphthalenesulfonic acid,

naphthalenedisulfonic acid, methanesulfonic acid, ethanesulfonic acid and the like. The chemical modification of a pharmaceutical compound (i.e. a drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See,
5 e.g., Stahl, P. H., and Wermuth, G., (editors), Handbook of Pharmaceutical Salts, Verlag Helvetica Chimica Acta (VHCA), Zürich, (2002) or Bastin, R.J., et al., Organic Proc. Res. Dev. 4 (2000) 427-435.

Preferred are the pharmaceutically acceptable salts, which are formed with p-toluenesulfonic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, methanesulfonic acid and hydrochloric acid.
10

The compounds of formula I can contain one or several chiral centers and can then be present in a racemic or in an optically active form. The racemates can be separated according to known methods into the enantiomers. For instance, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-camphorsulfonic acid. Alternatively separation of the enantiomers can also be achieved by using chromatography on chiral HPLC-phases which are commercially available.
15

The compounds of formula I and their pharmaceutically acceptable salts possess valuable pharmacological properties. It has been found that said compounds inhibit the HER-signalling pathway and show anti-proliferative activity. Consequently the compounds of the present invention are useful in the therapy and/or prevention of illnesses with known over-expression of receptor tyrosine kinases of the HER-family like HER-2 and EGFR (HER-1), especially in the therapy and / or prevention of illnesses mentioned above. The activity of the present compounds as HER-signalling pathway inhibitors is demonstrated by the following biological assay:
20
25

CellTiter-GloTM assay in HEK293 cells

The CellTiter-GloTM Luminescent Cell Viability Assay (Promega) is a homogeneous method of determining the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells.
30

- 15 -

HEK293 cells (human embryonic kidney cell line transformed by Adenovirus 5 fragments, ATCC-No. CRL 1573) were cultivated in Dulbecco's Modified Eagle Medium (DMEM) with GlutamaxTM (Invitrogen, 31966-021), 5% Fetal Calf Serum (FCS, Sigma Cat-No. F4135 (FBS)), 100Units/ml penicillin / 100µg/ml streptomycin (= Pen/Strep from Invitrogen Cat. No. 15140). , For the assay the cells were seeded in 384 well plates, 5000 cells per well, in the same medium. The next day the test compounds were added in various concentrations ranging from 3 µM to 0.00015 µM (10 concentrations, 1:3 diluted). After 7 days the CellTiter-GloTM assay was done according to the instructions of the manufacturer (CellTiter-GloTM Luminescent Cell Viability Assay, from Promega). In brief: the cell-plate was equilibrated to room temperature for approximately 30 minutes and than the CellTiter-GloTM reagent was added. The contents were carefully mixed for 15 minutes to induce cell lysis. After 45 minutes the luminescent signal was measured in Victor 2, (scanning multiwell spectrophotometer, Wallac).

15 Details:

1st day:

- Medium: Dulbecco's Modified Eagle Medium (DMEM) with GlutamaxTM (Invitrogen, 31966-021), 5 % Fetal Calf Serum (FCS, Sigma Cat-No. F4135 (FBS)), Pen/Strep (Invitrogen Cat. No. 15140).
- 20 - HEK293 (ATCC-No. CRL 1573) : 5000 cells in 60 µl per well of 384 well plate (Greiner 781098, white plates)
- Incubate 24 h at 37°C, 5% CO₂

2nd day: Induction (Substance testing):

25 In general the dilution steeps are 1:3

- a) Add 8 µl of 10 mM stock solution of compound to 72 µl DMSO
- b) dilute 9x 1:3 (always 30 µl to 60 µl DMSO) in this DMSO dilution row (results in 10 wells with concentrations from 1000 µM to 0.06 µM)
- c) dilute each concentration 1: 4.8 (10 µl compound dilution to 38 µl medium)
- 30 d) dilute each concentration 1: 10 (10 µl compound dilution to 90 µl medium)
- e) add 10 µl of every concentration to 60 µl medium in the cell plate

- 16 -

- -resulting in final concentration of DMSO : 0.3 % in every well
- and resulting in final concentration of compounds from 3 μ M to 0.00015 μ M
- Incubate 168 h (7 days) at 37°C, 5% CO₂

5

Analysis:

- Add 30 μ l CellTiter-GloTM Reagent/well,
- shake 15 minutes at room temperature
- incubate further 45 minutes at room temperature without shaking.

10

Measurement:

- Victor 2 scanning multiwell spectrophotometer (Wallac), Luminescence mode
- Determine IC₅₀ with XL-fit (XLfit software (ID Business Solution Ltd., Guilford, Surrey, UK)).

15

With all compounds a significant inhibition of HEK293 cell viability was detected, which is exemplified by the compounds shown in Table 1. The reference compound as used herein is 4-[1,2,3]Triazol-1-yl-1-(4-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one (Example 42, p. 148, WO 03/059907).

20

Results: Table 1

Examples	IC ₅₀ HEK293 [nM]
Reference compound	164
1	17.9
2	21.1
3	29.9

In vivo assay on tumor inhibition:

25

To generate primary tumors, Non-Small-Cell Lung Cancer (NSCLC) (e.g. Calu-3 (ATTC HTB-55) or A549 (ATTC CCL-185)) cells ($4-5.0 \times 10^6$ in a volume of 100 μ l) are injected subcutaneously into the left flank of female SCID beige (Severe

Combined Immunodeficient / beige mice available from Charles River, Sulzfeld, Germany) or BALB/c nude (BALB/c Nude Spontaneous Mutant Mice (homozygotes) available from Taconic Europe, Ry, Denmark) mice. The cells are thawed and expanded in vitro before use in the experiment. Mice are assigned to the treatment groups 14-21 days after cell injection. For grouping (n = 10-15 mice per group), the animals are randomized to get a similar mean primary tumor volume of ca. 100-150 mm³ per group. The test compounds are administered orally once per day as a suspension in 7.5% gelatine 0.22% NaCl with an administration volume of 10 ml/kg based on actual body weights. Treatment is initiated one day after staging, and carried out until day 20-50, the final day of the study. The subcutaneous primary tumors are measured twice weekly, starting prior to randomisation, in two dimensions (length and width) using an electronic caliper. The volume of the primary tumor is calculated using the formula: $V[\text{mm}^3] = (\text{length} [\text{mm}] \times \text{width} [\text{mm}] \times \text{width} [\text{mm}]) / 2$. In addition, the body weight of all animals is recorded at least twice weekly. Finally, at the end of the study the tumors are explanted and weighed.

The compounds according to this invention and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions. The pharmaceutical compositions can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The above-mentioned pharmaceutical compositions can be obtained by processing the compounds according to this invention with pharmaceutically inert, inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

- 18 -

The pharmaceutical compositions can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

5 Pharmaceutical compositions comprise e.g. the following:

a) Tablet Formulation (Wet Granulation):

Item	Ingredients	mg/tablet			
1.	Compound of formula (I)	5	25	100	500
2.	Lactose Anhydrous DTG	125	105	30	150
3.	Sta-Rx 1500	6	6	6	30
4.	Microcrystalline Cellulose	30	30	30	150
5.	Magnesium Stearate	1	1	1	1
	Total	167	167	167	831

Manufacturing Procedure:

1. Mix items 1, 2, 3 and 4 and granulate with purified water.
- 10 2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment.
4. Add item 5 and mix for three minutes; compress on a suitable press.

b) Capsule Formulation:

Item	Ingredients	mg/capsule			
1.	Compound of formula (I)	5	25	100	500
2.	Hydrous Lactose	159	123	148	---
3.	Corn Starch	25	35	40	70
4.	Talc	10	15	10	25
5.	Magnesium Stearate	1	2	2	5
	Total	200	200	300	600

Manufacturing Procedure:

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

5

c) Micro suspension

1. Weigh 4.0 g glass beads in custom made tube GL 25, 4 cm (the beads fill half of the tube).
2. Add 50 mg compound, disperse with spatulum and vortex.
- 10 3. Add 2 ml gelatin solution (weight beads: gelatin solution = 2:1) and vortex.
4. Cap and wrap in aluminium foil for light protection.
5. Prepare a counter balance for the mill.
6. Mill for 4 hours, 20/s in a Retsch mill (for some substances up to 24 hours at 30/s).
- 15 7. Extract suspension from beads with two layers of filter (100 μ m) on a filter holder, coupled to a recipient vial by centrifugation at 400 g for 2 min.
8. Move extract to measuring cylinder.
9. Repeat washing with small volumes(here 1 ml steps) until final volume is reached or extract is clear.
- 20 10. Fill up to final volume with gelatin and homogenise.

The above described preparation yields micro-suspensions of the compounds of formula I with particle sizes between 1 and 10 μ m. The suspensions are suitable for oral applications and can be used in the in vivo assay described above.

- 25 Medicaments containing a compound of the present invention or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of the present invention and/or pharmaceutically acceptable salts and, if desired, one or more other therapeutically
- 30 valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

- 20 -

In accordance with the invention the compounds of the present invention as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses. Based on their HER-signalling pathway inhibition and their antiproliferative activity, said compounds are useful for the treatment of diseases such as cancer in humans or animals and for the production of corresponding medicaments. The dosage depends on various factors such as manner of administration, species, age and/or individual state of health.

Another embodiment of the invention is a pharmaceutical composition, containing one or more compounds of formula I together with pharmaceutically acceptable excipients.

Still another embodiment of the invention is said pharmaceutical composition for the inhibition of tumor growth.

Still another embodiment of the invention is the use of a compound of formula I for the treatment of cancer.

Still another embodiment of the invention is the use of a compound of formula I for the manufacture of corresponding medicaments for the inhibition of tumor growth.

The following examples and references are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

Examples:

Example 1:

4-[1,2,3]Triazol-1-yl-1-(4-{2-[(E)-2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one

To a cooled solution of 10.8 g (0.1 mol) anisole in 100 ml anhydrous toluene 13.3 g (0.1 mol) aluminium trichloride was added in portions over 15 minutes at -10°C then 15.5 g (12.3 ml, 0.1 mmol) 4-chloro-butyryl chloride were added over 15

- 21 -

minutes keeping the temperature at -10°C. After stirring for additional 30 minutes at -10°C the reaction mixture was hydrolyzed and the layers were separated. The aqueous layer was extracted with toluene (three times 100 ml) and the combined organic layers were dried and evaporated to yield 20.8 g (97%) 4-chloro-1-(4-methoxy-phenyl)-butan-1-one as a light beige liquid that solidified on standing. The product was used without further purification.

¹H-NMR (400 MHz, D₆-DMSO): δ= 2.06 (quintet, 2H); 3.12 (t, 2H); 3.71 (t, 2H); 3.85 (s, 3H); 7.05 (d, 2H); 7.95 (d, 2H).

10.6 g (50 mmol) 4-Chloro-1-(4-methoxy-phenyl)-butan-1-one, 20 ml 2-methyl-2-butanol, 5.2 g (75 mmol) 1H-[1,2,3]-triazole, 9.5 g (57 mmol) potassium iodide and 3.0 g (75 mmol) NaOH were stirred at 100°C for 4 h. After removal of solvents in vacuo, the residue was partitioned between toluene and water. Washing of the toluene phase twice with water, drying over sodium sulphate and evaporation gave an oily residue that was dissolved in 80 ml diisopropyl ether/ethyl acetate (1:2). The solution was kept at 20°C during the addition of 2.8 ml methanesulfonic acid and stirred at room temperature for 2h. The formed precipitate was isolated, washed with cold diethyl ether and dried at 40°C in vacuo to give 1-(4-methoxy-phenyl)-4-[1,2,3]triazol-1-yl-butan-1-one methanesulfonate. Yield: 2.25 g (13%).

¹H-NMR (400 MHz, D₆-DMSO): δ= 2.16 (quintet, 2H); 2.45 (s, 3H); 3.00 (t, 2H); 3.84 (s, 3H); 4.46 (t, 2H); 7.04 (d, 2H); 7.76 (s, 1H); 7.92 (d, 2H); 8.19 (s, 1H).

1.70 g (5.0 mmol) 1-(4-Methoxy-phenyl)-4-[1,2,3]triazol-1-yl-butan-1-one methane-sulfonate and 7 ml 47% aqueous HBr were heated to 80°C overnight. After diluting with 10 ml water and cooling to 0°C the mixture was alkalized (pH 12.6) by dropwise addition of 4N NaOH and extracted three times with toluene. Concentration of the toluene phase in vacuo gave 0.05 g recovered starting material. The aqueous phase was cooled and adjusted to pH = 6.3 by addition of 6 N HCl. The resulting precipitate was isolated and dried in vacuo at 40°C to give 1-(4-hydroxy-phenyl)-4-[1,2,3]triazol-1-yl-butan-1-one. Yield: 0.96 g (83%).

¹H-NMR (400 MHz, D₆-DMSO): δ= 2.14 (quintet, 2H); 2.94 (t, 2H); 4.45 (t, 2H); 6.85 (d, 2H); 7.73 (s, 1H); 7.82 (d, 2H); 8.16 (s, 1H); 10.34 (s, 1H).

- 22 -

To a solution of 116 mg (0.5 mmol) 1-(4-hydroxy-phenyl)-4-[1,2,3]triazol-1-yl-butan-1-one in 10 ml 2-butanone 98 mg (0.3 mmol) cesium carbonate was added and the mixture was stirred at 60°C for 30 minutes. Then 152 mg (0.5 mmol) 4-chloromethyl-2-[(E)-2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazole and 83 mg (0.5 mmol) potassium iodide were added and the mixture was stirred at 60°C overnight. After removal of all volatiles in vacuo the residue was purified by column chromatography on silica (ethyl acetate) to give 4-[1,2,3]triazol-1-yl-1-(4-{2-[(E)-2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one. Yield: 200 mg (81%) white solid.

¹H-NMR (400 MHz, D₆-DMSO): δ= 2.16 (quintet, 2H); 3.00 (t, 2H); 4.46 (t, 2H); 5.14 (s, 2H); 7.16 (d, 2H); 7.22 (d, J=16.2 Hz, 1H); 7.41 (d, 2H); 7.58 (d, J=16.2 Hz, 1H); 7.73 (s, 1H); 7.87 (d, 2H); 7.93 (d, 2H); 8.17 (s, 1H); 8.27 (s, 1H).

Example 2:

(rac)-4-[1,2,3]Triazol-1-yl-1-(4-{2-[(E)-2-(4-trifluoro-methoxyphenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-ol

To a solution of 10 mg (0.26 mmol) sodium borohydride in 10 ml methanol 100 mg (0.20 mmol) 4-[1,2,3]triazol-1-yl-1-(4-{2-[(E)-2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one were added in portions and the mixture was stirred at room temperature overnight. The reaction was monitored by thin layer chromatography (silica/ethyl acetate R_f= 0.27) and an additional amount of 10 mg sodium borohydride was added and stirring was continued for 3 hours to complete the reaction. After removal of all volatiles in vacuo 20 ml water were added to the residue and the mixture was extracted with diethyl ether (three times 15 ml). The combined organic layers were dried over sodium sulfate and evaporated to dryness. Yield: 97 mg (97%) white solid.

¹H-NMR (400 MHz, D₆-DMSO): δ= 1.41-1.61 (m, 2H); 1.69-1.95 (m, 2H); 4.37 (t, 2H); 4.45-4.55 (t, 1H); 4.99 (s, 2H); 5.14 (d, J=4.5 Hz, 1H); 6.97 (d, 2H); 7.21 (d, J=16.2 Hz, 1H); 7.22 (d, 2H); 7.41 (d, 2H); 7.57 (d, J=16.2 Hz, 1H); 7.69 (s, 1H); 7.87 (d, 2H); 8.09 (s, 1H); 8.21 (s, 1H).

- 23 -

Example 3:

4-[1,2,3]Triazol-1-yl-1-(4-{2-[(*E*)-2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one

5 4-[1,2,3]Triazol-1-yl-1-(4-{2-[(*E*)-2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one was prepared analogously to example 1.


¹H-NMR (400 MHz, D₆-DMSO): δ= 2.16 (quintet, 2H); 3.00 (t, 2H); 4.46 (t, 2H); 5.14 (s, 2H); 7.16 (d, 2H); 7.31 (d, J=16.2 Hz, 1H); 7.59 (d, J=16.2 Hz, 1H); 7.73 (s, 1H); 7.34 (d, 2H); 7.88 (d, 2H); 7.93 (d, 2H); 8.17 (s, 1H); 8.29 (s, 1H).

List of References

- Bastin, R.J., et al., Organic Proc. Res. Dev. 4 (2000) 427-435
- Baselga, J., and Hammond, L.A., Oncology 63 (Suppl. 1) (2002) 6-16
- Chan, A.C., and Shaw, A.S., Curr. Opin. Immunol. 8 (1996) 394-401
- 5 EP 1 270 571
- Larsen et al., Ann. Reports in Med. Chem., 1989, Chpt. 13
- Ranson, M., and Sliwkowski, M.X., Oncology 63 (suppl. 1) (2002) 17-24
- Stahl, P. H., and Wermuth, G., (editors), Handbook of Pharmaceutical Salts, Verlag
Helvetica Chimica Acta (VHCA), Zürich (2002)
- 10 Wilks et al., Progress in Growth Factor Research 97 (1990) 2
- WO 01/77107
- WO 03/031442
- WO 03/059907
- WO 98/03505
- 15 Wright, C., et al., Br. J. Cancer 65 (1992) 118-121
- Yarden, Y., and Ullrich, A., Annu. Rev. Biochem. 57 (1988) 443-478

Patent Claims

1. A compound of formula I



formula I,

5

wherein

R¹ is -O-alkyl;
-S-alkyl; all alkyl groups being optionally substituted one or several
times by halogen;

10

R² is hydrogen or halogen;

R³ is hydrogen, alkyl or halogen;

W is -C(O)-, -CH(OH)- or -C(alkyl)(OH)-

15

and pharmaceutically acceptable salts thereof.

2. The compounds according to claim 1, wherein

R² is hydrogen; and

20

R³ is hydrogen or alkyl.

3. The compounds according to claim 1, wherein

R² is hydrogen; and

R³ is hydrogen.

25

- 26 -

4. The compounds according to anyone of claim 1 to 3, wherein

W is -C(O)-.

5. The compounds according to anyone of claim 1 to 3, wherein

5 W is -CH(OH)-.

6. The compounds according to claim 1 selected from the group consisting of:


4-[1,2,3]Triazol-1-yl-1-(4-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-ol;

10 4-[1,2,3]Triazol-1-yl-1-(4-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one; and

4-[1,2,3]Triazol-1-yl-1-(4-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-ol.

15 7. A process for the manufacture of the compounds of formula I in claim 1 , wherein

(a) the compound of formula V




formula V,

20 wherein R³ has the significance as given in formula I in claim 1 and W is -C(O)-,


- 27 -

is reacted with a compound of formula VI



formula VI,

5 wherein R¹ and R² have the significance given in formula I in claim 1, to give the respective compound of formula Ia;




formula Ia

10

wherein R¹, R² and R³ have the significance given in formula I in claim 1,

(b) if desired, the compound of formula Ia is reduced to give the respective compound of formula Ib and

15



formula Ib

20

wherein R¹, R² and R³ have the significance given in formula I in claim 1,

- 28 -

(c) said compound of formula Ia or Ib is isolated from the reaction mixture, and

(d) if desired, converted into a pharmaceutically acceptable salt.

5

8. A pharmaceutical composition, containing one or more compounds according to claims 1 to 6 together with pharmaceutically acceptable excipients.

10

9. The pharmaceutical composition according to claim 8 for the inhibition of tumor growth.

10. The use of a compound according to claims 1 to 6 for the manufacture of corresponding medicaments for the inhibition of tumor growth.

11. The use of a compound in any one of claims 1 to 6 for the treatment of cancer.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/010127

A. CLASSIFICATION OF SUBJECT MATTER C07D413/12 A61K31/422 A61P35/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, BEILSTEIN Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/059907 A (TAKEDA CHEMICAL INDUSTRIES, LTD; TASAKA, AKIHIRO; TANIGUCHI, TAKAHIKO;) 24 July 2003 (2003-07-24) cited in the application the whole document -----	1-11
☐ Further documents are listed in the continuation of box C. ☒ Patent family members are listed in annex.		
* Special categories of cited documents :		
* A* document defining the general state of the art which is not considered to be of particular relevance * E* earlier document but published on or after the international filing date * L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) * O* document referring to an oral disclosure, use, exhibition or other means * P* document published prior to the international filing date but later than the priority date claimed * T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention * X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone * Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. * &* document member of the same patent family		
Date of the actual completion of the international search 23 December 2005		Date of mailing of the international search report 05/01/2006
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Grassi, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/010127

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03059907 A	24-07-2003	AU 2003203170 A1	30-07-2003